Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,231,725 papers from all fields of science
Search
Sign In
Create Free Account
AZD8186
Known as:
AZD-8186
, PI3Kbeta Inhibitor AZD8186
An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Aniline Compounds
Chromones
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
Yi-Hui Wu
,
Yu-Fang Huang
,
Chien-Chin Chen
,
Chia-Yen Huang
,
C. Chou
Frontiers in Pharmacology
2020
Corpus ID: 211723485
Epithelial ovarian carcinoma (EOC) is the most lethal gynecological malignancy. Herein, we sought to determine the efficacy of…
Expand
2018
2018
A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically.
Xinshuai Wang
,
Xue-zhen Ding
,
+9 authors
Yuanpei Li
Nanomedicine : nanotechnology, biology, and…
2018
Corpus ID: 51725181
2017
2017
Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors
J. Lynch
,
U. Polanska
,
+15 authors
S. Barry
Clinical Cancer Research
2017
Corpus ID: 8448258
Purpose: PTEN-null tumors become dependent on the PI3Kβ isoform and can be targeted by molecules such as the selective PI3K…
Expand
2017
2017
A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor…
A. Hansen
,
G. Shapiro
,
+17 authors
L. Siu
2017
Corpus ID: 79773922
2570Background: Loss of PTEN function leads to increased PI3Kβ signalling. AZD8186 (AZD) exhibits significant anti-tumour…
Expand
2016
2016
The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor
Juliana Maynard
,
Sally-Ann Emmas
,
+6 authors
S. Barry
EJNMMI Research
2016
Corpus ID: 13039554
BackgroundThe phosphatidylinositol 3 kinase (PI3K) signalling pathway is frequently altered in human cancer and a promising…
Expand
2016
2016
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen
J. Lynch
,
R. Mcewen
,
+4 authors
B. Davies
Oncotarget
2016
Corpus ID: 18535311
Selective phosphoinositide 3-kinase (PI3K)/AKT/mTOR inhibitors are currently under evaluation in clinical studies. To identify…
Expand
Review
2015
Review
2015
PI3K inhibitors in inflammation, autoimmunity and cancer
A. Stark
,
S. Sriskantharajah
,
E. Hessel
,
K. Okkenhaug
Current opinion in pharmacology
2015
Corpus ID: 17212412
Highly Cited
2015
Highly Cited
2015
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
R. Marques
,
A. Aghai
,
+8 authors
W. V. van Weerden
European urology
2015
Corpus ID: 30229792
Highly Cited
2015
Highly Cited
2015
Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of…
B. Barlaam
,
S. Cosulich
,
+15 authors
Nicolas Warin
Journal of medicinal chemistry
2015
Corpus ID: 24231832
Several studies have highlighted the dependency of PTEN deficient tumors to PI3Kβ activity and specific inhibition of PI3Kδ has…
Expand
Highly Cited
2014
Highly Cited
2014
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Urs J Hancox
,
S. Cosulich
,
+21 authors
S. Barry
Molecular Cancer Therapeutics
2014
Corpus ID: 24994771
Loss of PTEN protein results in upregulation of the PI3K/AKT pathway, which appears dependent on the PI3Kβ isoform. Inhibitors of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE